N-3c01(q2w)

Preclinical

HHefei Xinzhu Biological Technology Co., Ltd.

N-3c01(q2w) is one of 22 therapeutic programs targeting Advanced Malignant Solid Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Malignant Solid TumorsRecruiting

Advanced Malignant Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

35 competitors in Advanced Malignant Solid Tumors

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

2 2

Eloxatin

Teva

Phase 2

2 3

Opdivo

Bristol-Myers Squibb

Phase 2

2 4

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 6

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 7

JS207

SShanghai Junshi Bioscience Co., Ltd.

Phase 2

2 8

QLS31905

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 9

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 10

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Advanced Malignant Solid Tumors

NCT07639450

Clinical

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination With PD-(L)1 Monoclonal Antibody in Patients With Advanced Malignant Solid Tumors

Recruiting·HHefei Xinzhu Biological Technology Co., Ltd.·Preclinical·NCT07639450·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for N-3c01(q2w). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for N-3c01(q2w). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hefei Xinzhu Biological Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: HHefei Xinzhu Biological Technology Co., Ltd.

N-3c01(q2w)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News